XLO

Price & events

Pipeline stages · 1 programs

Pipeline · 1 trials · 1 upcoming

Catalyst news & presentations · 14

• 2027Guided 40%trial initiationsecondaryCLDN18.2 masked T cell engager · IND submission for masked T cell engager.SEC 8-K
• 2H 2027Guided 55%readoutPhase 1XTX501 · Initial Phase 1 data for XTX501.SEC 8-K
• 2027Guided 40%trial initiationsecondaryPSMA+STEAP1 masked T cell engager · IND submission for multi-specific masked T cell engager with co-stimulation.SEC 8-K
• 1H 2027Guided 55%readoutPhase 2efarindodekin alfa · Option data package for masked IL-12 collaboration with Gilead.SEC 8-K
• mid 2026trial initiationsecondaryXTX501 · IND submission for PD-1/masked IL-2 bispecific.SEC 8-K
• November 7, 2025conferencedata presentationsecondaryPhase 2vilastobart · Late-breaking poster presentation of Phase 2 data at SITC 40th Annual Meeting.SEC 8-K
• 2025-09-09partnershipefarindodekin alfa · Achieved $17.5 million development milestone under license agreement with Gilead.SEC 8-K
• September 9, 2025trial initiationsecondaryPhase 2efarindodekin alfa · Initiation of patient dosing in Phase 2 portion of ongoing Phase 1/2 trial.SEC 8-K
• ASCO 2025 Gastrointestinal Cancer Symposiumconferencedata presentationsecondaryPhase 2vilastobart · Initial Phase 2 data of vilastobart in combination with atezolizumabSEC 8-K
• first quarter of 2025readoutPhase 2vilastobart · Phase 2 data for vilastobart in combination with atezolizumab in total of approximately 40 patients.SEC 8-K
• 2025-02-10partnershipCollaboration with AbbVie for up to four programs using tumor-activation technology; includes $52M upfront and up to ~$2.1B in milestones.SEC 8-K
• fourth quarter of 2024readoutPhase 2vilastobart · Initial Phase 2 data for vilastobart in combination with atezolizumab in approximately 20 patients.SEC 8-K
• fourth quarter of 2024readoutPhase 1XTX301 · Phase 1 data for XTX301, a tumor-activated IL-12.SEC 8-K
• 2024-03-27partnershipExclusive license agreement between Xilio and Gilead Sciences, Inc.SEC 8-K